Ann: Regeneus and AGC collaborate on Progenza in Japan, page-2

My goodness. dream deal with huge multinational. Couldn't have asked for a better outcome.

No upfront costs for rgs.
5.5 mill in rgs pocket immediately.
Another 16 mill to enter into rgs pocket throughout development.
Continual royalty and licencing revenue for both parties.
Our multinational partner to cover all costs of manufacturing.
Our multinational partner has access and connections with major biopharmas in japan and globally (potential avenue for fast track and commercialisation of our other technologies anyone???)

This is the one we were waiting for fellas. The patient get rewarded. Now to sit back and enjoy the ride.